| abstract |
A method of, and preparation for, treatment of human patients to inhibit platelet aggregation is provided. Generally, the method comprises the administration of acetylsalicylic acid (ASA) to reduce risk of myocardial infarction. The method comprises an administration once daily of a preparation permitting two pulses of ASA to be absorbed, the first pulse preferably being absorbed within two hours after administration and the second pulse being absorbed about six hours to eighteen hours after administration. In the preferred embodiment, the method comprises a total administration of 300 milligrams of ASA, once daily, with the first pulse preferably containing about one-third of the ASA. The method will inhibit platelet aggregation, while at the same time generally minimizing undesirable effects such as gastrointestinal bleeding. A preparation is provided for use with the method comprising a pill with a central core containing about 200 milligrams of ASA, surrounded by a protective coating preventing absorption of the central core until between about six hours and eighteen hours after administration. Adhering to the central core and protective coating is an outer layer of ASA prepared for absorption into the portal circulatory system during a time period of within about two hours following administration of the pill. |